Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$3.22 CAD
Change Today -0.04 / -1.23%
Volume 2.5K
I On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 3:59 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

intellipharmaceutics interna (I) Snapshot

Open
C$3.22
Previous Close
C$3.26
Day High
C$3.32
Day Low
C$3.15
52 Week High
04/29/14 - C$5.15
52 Week Low
08/27/14 - C$2.14
Market Cap
75.5M
Average Volume 10 Days
12.6K
EPS TTM
C$-0.17
Shares Outstanding
23.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTELLIPHARMACEUTICS INTERNA (I)

Related News

No related news articles were found.

intellipharmaceutics interna (I) Related Businessweek News

No Related Businessweek News Found

intellipharmaceutics interna (I) Details

Intellipharmaceutics International Inc., a pharmaceutical company, engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under abbreviated new drug application stage include Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorders; Effexor XR, a venlafaxine hydrochloride extended-release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, as well as bipolar and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy; and Pristiq, a tablet for depression. The company is also developing Oleptro, a trazodone hydrochloride extended release tablet for treating depression; Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, and fibromyalgia. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.

46 Employees
Last Reported Date: 02/27/15

intellipharmaceutics interna (I) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $582.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $582.0K
Chief Financial Officer
Total Annual Compensation: $5.2K
Vice President of Legal Affairs & Licensing, ...
Total Annual Compensation: $132.2K
Compensation as of Fiscal Year 2014.

intellipharmaceutics interna (I) Key Developments

Intellipharmaceutics International Inc. Reports Audited Consolidated Earnings Results for the Full Year Ended November 30, 2014

Intellipharmaceutics International Inc. reported audited consolidated earnings results for the full year ended November 30, 2014. Loss from operations for the year ended November 30, 2014 was $3.5 million compared with loss from operations of $6.8 million for the year ended November 30, 2013, or a 48% reduction. The company recorded a net loss for the year ended November 30, 2014 of $3.9 million, or $0.17 per common share, compared with a loss of $11.5 million, or $0.58 per common share for the year ended November 30, 2013. The decreased loss can be attributed to an increase in revenue recognized from the payments received from the commercial sales of dexmethylphenidate hydrochloride extended-release generic of Focalin XR? capsules in the year ended November 30, 2014 compared to the prior year. For the year ended November 30, 2014, net cash flows used in operating activities decreased to $1.7 million as compared to $6.9 million for the year ended November 30, 2013. The decrease was due to the payments received from the commercial sales of generic Focalin XR ? (dexmethylphenidate hydrochloride extended-release) capsules by Par for the 15 and 30 mg strengths, partially offset by the increase in R&D expenses and increase in selling, general and admin.

IntelliPharmaCeutics International Inc. Signs Exclusive Licensing and Manufacturing Agreement with Teva Pharmaceuticals USA, Inc

Intellipharmaceutics International Inc. has entered into an agreement with Teva Pharmaceuticals USA, Inc. by which the Company has granted Teva an exclusive license to market in the U.S. an extended release drug product candidate for which Intellipharmaceutics currently has an abbreviated new drug application pending for U.S. Food and Drug Administration approval. Under the agreement with Teva, subject to certain conditions, Intellipharmaceutics has agreed to manufacture and supply the product exclusively for Teva and Teva has agreed that Intellipharmaceutics will be its sole supplier of the product to be marketed in the U.S. There can be no assurance as to when or if the product will be approved by the FDA or that, if so approved, it will be successfully commercialized and produce significant revenue for the Company.

IntelliPharmaCeutics International Inc. to Report Q4, 2014 Results on Feb 19, 2015

IntelliPharmaCeutics International Inc. announced that they will report Q4, 2014 results on Feb 19, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I:CN C$3.22 CAD -0.04

I Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,686 GBp -5.00
Durect Corp $1.88 USD +0.13
Lupin Ltd 1,955 INR -18.15
Torrent Pharmaceuticals Ltd 1,138 INR +3.90
View Industry Companies
 

Industry Analysis

I

Industry Average

Valuation I Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.8x
Price/Book 12.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELLIPHARMACEUTICS INTERNA, please visit www.intellipharmaceutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.